Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies

被引:1
|
作者
Sugiura-Ogasawara, Mayumi [1 ]
Atsumi, Tatsuya [2 ]
Yamada, Hideto [3 ]
Kitaori, Tamao [1 ]
Ozaki, Yasuhiko [1 ]
Katano, Kinue [1 ]
Murashima, Atsuko [4 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Nagoya, Aichi 4678601, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan
[3] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo 657, Japan
[4] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Tokyo, Japan
关键词
Antiphospholipid antibody; lupus anticoagulant; obstetric antiphospholipid syndrome; recurrent pregnancy loss; survey; RECURRENT PREGNANCY LOSS; ASPIRIN PLUS HEPARIN; LUPUS ANTICOAGULANT; ANTICARDIOLIPIN ANTIBODIES; WOMEN; AUTOANTIBODIES; PREDICTOR; RECOGNIZE; UPDATE; TRIAL;
D O I
10.3109/14397595.2015.1023978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The international classification criteria (CC) for definite antiphospholipid syndrome (APS) recommend confirmation of the sustained presence, for at least 12 weeks, of both lupus anticoagulant (LA), as determined by aPTT and RVVT, and anti beta 2glycoprotein I (beta 2GPI) or anticardiolipin (aCL) IgG and/or IgM. However, it remains unclear whether obstetricians comply with the aforementioned CC for the diagnosis of APS in daily clinical practice. We performed a nationwide survey to examine the attitudes of Japanese obstetricians toward the use of assays for antiphospholipid antibodies (aPLs). Methods. A questionnaire was sent to 2,700 obstetric facilities where maternity checkups are car-ried out. The types of assays conducted for aPLs, ascertainment of persistence of the antibodies for at least 12 weeks, and the cutoff points used for the assays were examined. Results. Of the facilities surveyed, 61.5% carried out the assay(s) only once. In regard to the type of assay performed, 97.1% carried out the assay for aCL IgG and/or beta 2GPI-dependent aCL, while 67.9% performed the LA-aPTT and/or LA-RVVT assay. Only 8.8% carried out assays for both LA. As for the cutoff points used, 98% of the facilities used lower cutoff points described in the manufacturers' manuals rather than the cutoff values recommended in the CC. Conclusion. Thus, only a limited number of facilities adhered precisely to the CC for the diagnosis of APS. Inappropriate treatment and unnecessary expense are potentially major concerns when facilities overdiagnose APS using lower cutoff points or without ascertaining the persistence of the antibodies for at least 12 weeks. On the other hand, some patients miss the opportunity to be treated for APS because of the absence of testing for LA.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [31] Antiphospholipid antibodies determined by enzyme-linked immunosorbent assays in patients with antiphospholipid syndrome, rheumatoid arthritis, and systemic lupus erythematosus
    Tellez, Goitybell Martinez
    Rives, Barbara Torres
    Hendrich, Maite Martiatu
    Rodriguez, Vicky Sanchez
    Rosales, Yaima Zuniga
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2024, 58 (04): : 325 - 331
  • [32] Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?
    Navarro-Sabate, A.
    Font, R.
    Espinas, J. A.
    Sola, J.
    Martinez-Soler, F.
    Gil-Gil, M.
    Vinas, G.
    Tibau, A.
    Borrell, M.
    Segui, M.
    Margeli, M.
    Servitja, S.
    Perez, C.
    Domenech, M.
    Nava, M.
    Marin, M.
    Gonzalez, S.
    Borras, J. M.
    CANCERS, 2025, 17 (02)
  • [33] Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study
    Russi, Alberto
    Damuzzo, Vera
    Chiumente, Marco
    Pigozzo, Jacopo
    Cesca, Marco
    Chiarion-Sileni, Vanna
    Palozzo, Angelo Claudio
    JOURNAL OF CHEMOTHERAPY, 2017, 29 (04) : 245 - 251
  • [34] Survey of Real-World Research Workforce, Training, and Education: Report from the DIA Real-World Outcomes Task Force
    Gliklich, Richard
    Glennie, Judith
    Mattox, Pattra W.
    Graff, Jennifer S.
    Garner, Sarah
    Marrone, Christopher M.
    Shaya, Fadia T.
    Hansen, Jan
    Lewin, Jack
    Blackburn, Stella
    Berger, Marc
    Dreyer, Nancy A.
    DRUG INFORMATION JOURNAL, 2012, 46 (02): : 185 - 191
  • [35] Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective
    Zhu, Rui
    Vora, Bianca
    Menon, Sujatha
    Younis, Islam
    Dwivedi, Gaurav
    Meng, Zhaoling
    Datta-Mannan, Amita
    Manchandani, Pooja
    Nayak, Satyaprakash K.
    Tammara, Brinda
    Garhyan, Parag
    Iqbal, Shahed
    Dagenais, Simon
    Chanu, Pascal
    Mukherjee, Arnab
    Ghobadi, Cyrus
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (04) : 751 - 767
  • [36] Survey of Real-World Research Workforce, Training, and Education: Report from the DIA Real-World Outcomes Task Force
    Richard Gliklich
    Judith Glennie
    Pattra W. Mattox
    Jennifer S. Graff
    Sarah Garner
    Christopher M. Marrone
    Fadia T. Shaya
    Jan Hansen
    Jack Lewin
    Stella Blackburn
    Marc Berger
    Nancy A. Dreyer
    Drug information journal : DIJ / Drug Information Association, 2012, 46 : 185 - 191
  • [37] Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience
    Patel, Rima
    Jin, Cao
    Jaber, Diana
    Casasanta, Nicole
    Jain, Mayuri
    Fu, Weijia
    Wu, Catherine
    Moshier, Erin
    Tiersten, Amy
    CLINICAL BREAST CANCER, 2025, 25 (03) : 283 - 290
  • [38] Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidencebased evaluation in the United States
    Wheeler, Cosette M.
    Torrez-Martinez, Norah E.
    Torres-Chavolla, Edith
    Parvu, Valentin
    Andrews, Jeffrey C.
    Du, Ruofei
    Robertson, Michael
    Joste, Nancy E.
    Cuzick, Jack
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 230 (02) : e1 - e11
  • [39] Coagulation Testing in Real-World Setting: Insights From a Comprehensive Survey
    Bang, Hae In
    Lee, Ja Young
    Kim, Hyun-Young
    Shin, Saeam
    Nam, Myung Hyun
    Kim, In-Suk
    Kim, Ji Myung
    Yoon, Jong-Hyun
    Shin, Myung-Geun
    Hwang, Sang Mee
    Kong, Sun-Young
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
  • [40] Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays
    Artim-Esen, Bahar
    Pericleous, Charis
    Mackie, Ian
    Ripoll, Vera M.
    Latchman, David
    Isenberg, David
    Rahman, Anisur
    Ioannou, Yiannis
    Giles, Ian
    ARTHRITIS RESEARCH & THERAPY, 2015, 17